Progyny vs Sotera Health
PGNY and SHC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PGNY and SHC compare
Sotera Health is the larger company, worth 1.7 times as much as Progyny ($4.7B against $2.8B).
On earnings, Sotera Health is cheaper: it trades at 29.1× trailing earnings, against 33.2× for Progyny.
Sotera Health grew revenue faster over the last twelve months (8.1% versus 5.5% for Progyny).
Sotera Health keeps more of each dollar of sales as profit, with a net margin of 13.4% compared with 6.8% at Progyny.
Progyny scores higher on the StockData Score (21 against 7 for Sotera Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PGNY | SHC |
|---|---|---|
| Size and price | ||
| Market cap | $2.8B | $4.7B |
| Share price | $36.18 | $16.61 |
| Change, 1 year | 50.3% | 2.2% |
| Change, 5 years | −39.0% | −26.3% |
| Beta (5Y) | 1.06 | 1.59 |
| Employees | 856 | 3,000 |
| StockData Score | ||
| Total score | 21 (better) | 7 |
| Valuation score | 3 (better) | 1 |
| Growth score | 6 (better) | 1 |
| Performance score | 6 (better) | 3 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 33.2× | 29.1× (better) |
| P/S | 2.1× (better) | 3.9× |
| P/B | 6.7× (better) | 7.1× |
| EV/EBITDA | 19.5× | – |
| P/FCF | 15.5× (better) | 42.1× |
| PEG | 1.13 | – |
| FCF yield | 6.5% (better) | 2.4% |
| Fair value | $38.02 | – |
| Margin of safety | 4.8% | – |
| Growth | ||
| Revenue growth (TTM) | 5.5% | 8.1% (better) |
| Revenue growth, 5Y average | 30.2% (better) | 7.3% |
| Net income growth (TTM) | 60.9% | 581% (better) |
| EPS growth (TTM) | 73.0% | 613% (better) |
| EPS growth, 5Y average | 6.7% | – |
| Profitability | ||
| Gross margin | 24.9% | 55.0% (better) |
| Operating margin | 9.4% | – |
| Net margin | 6.8% | 13.4% (better) |
| FCF margin | 13.4% (better) | 9.3% |
| Return on equity | 18.7% | 27.8% (better) |
| Return on invested capital | 40.0% | – |
| Financial health | ||
| Debt / equity | 0.00 | 3.21 (better) |
| Current ratio | 1.93 | 2.80 (better) |
| Altman Z-score | 9.94 (better) | 1.40 |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Buyback yield | 11.3% | – |
| Shareholder yield | 11.3% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 103% |
| Held by insiders | 2.6% | – |
| Insider net buying, 12 months | −$23.9M (better) | −$1.8B |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 6.4% | – |
Go deeper
- PGNY stock overview
- PGNY income statement
- PGNY valuation and score
- SHC stock overview
- SHC income statement
- SHC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.